Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the "LENAMAINT" Trial

被引：2
|
作者：
Sockel, Katja [1 ]
Greiner, Jochen [2 ]
Trenschel, Rudolf [3 ]
Unzicker, Christian [4 ]
Kobbe, Guido [5 ]
Finke, Jurgen [6 ]
Germing, Ulrich [7 ]
Mohr, Brigitte [1 ]
Beelen, Dietrich [8 ]
Ehninger, Gerhard [9 ]
Bornhaeuser, Martin [1 ]
Platzbecker, Uwe [1 ]
机构：
[1] Univ Hosp Dresden, Med Clin & Policlin 1, Dresden, Germany
[2] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany
[3] Univ Hosp, Clin Bone Marrow Transplantat, Essen, Germany
[4] Wuerzburg Univ, Med Ctr, Dept Internal Med 2, Wurzburg, Germany
[5] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[6] Univ Freiburg Klinikum, Dept Med 1, Freiburg, Germany
[7] Univ Hosp Dusseldorf, Dusseldorf, Germany
[8] Univ Hosp Essen, Dept Bone Marrow Transplantat, Essen, Germany
[9] Univ Hosp Carl Gustav Carus, Med Clin & Policlin 1, D-01307 Dresden, Germany
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3060.3060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：1320 / 1320
页数：1
相关论文
共 50 条
  • [21] RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
    Schuler, E.
    Schemenau, J.
    Giagounidis, A.
    Haase, D.
    Bueshce, G.
    Platzbecker, U.
    Nolte, F.
    Goetze, K.
    Schlenk, R. F.
    Ganser, A.
    Letsch, A.
    Luebbert, M.
    Schafhausen, P.
    Bug, G.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S62 - S62
  • [22] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    A Kuendgen
    M Lauseker
    A F List
    P Fenaux
    A A Giagounidis
    N A Brandenburg
    J Backstrom
    A Glasmacher
    J Hasford
    U Germing
    Leukemia, 2013, 27 : 1072 - 1079
  • [23] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
  • [24] Disease progression in del(5q) MDS patients treated with lenalidomide: analysis of risk factors and long-term outcome in 44 patients
    Giagounidis, A. A. N.
    Haase, S.
    Lohrbacher, V.
    Heinsch, M.
    Schuran, B.
    Aul, C.
    LEUKEMIA RESEARCH, 2007, 31 : S120 - S121
  • [25] Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
    Gudrun Göhring
    Aristoteles Giagounidis
    Guntram Büsche
    Hans Heinrich Kreipe
    Martin Zimmermann
    Eva Hellström-Lindberg
    Carlo Aul
    Brigitte Schlegelberger
    Annals of Hematology, 2010, 89 : 365 - 374
  • [26] Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.
    Gohring, Gudrun
    Giagounidis, Aristoteles
    Buesche, Guntram
    Kreipe, Hans
    Zimmermann, Martin
    Hellstrom-Lindberg, Eva
    Aul, Carlo
    Schlegelberger, Brigitte
    BLOOD, 2009, 114 (22) : 1469 - 1469
  • [27] Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
    Goehring, Gudrun
    Giagounidis, Aristoteles
    Buesche, Guntram
    Kreipe, Hans Heinrich
    Zimmermann, Martin
    Hellstroem-Lindberg, Eva
    Aul, Carlo
    Schlegelberger, Brigitte
    ANNALS OF HEMATOLOGY, 2010, 89 (04) : 365 - 374
  • [28] IMPACT OF 5Q BREAKPOINTS ON CLINICAL OUTCOMES IN PATIENTS WITH IPSS LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ISOLATED DEL(5Q) TREATED WITH LENALIDOMIDE IN THE MDS-004 STUDY
    Gohring, G.
    Giagounidis, A.
    List, A.
    Hellstrom-Lindberg, E.
    Sekeres, M.
    Mufti, G.
    Schlegelbergerl, B.
    Morrill, J.
    Wu, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2013, 98 : 80 - 80
  • [29] Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial
    Garcia-Manero, Guillermo
    Almeida, Antonio
    Fenaux, Pierre
    Gattermann, Norbert
    Giagounidis, Aristoteles
    Goldberg, Stuart L.
    Ozawa, Keiya
    Weaver, Jerry
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 213 - +
  • [30] A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities - Interim Results of the "AZALE" Trial.
    Platzbecker, Uwe
    Haase, Detlef
    Braulke, Friederike
    Bug, Gesine
    Goetze, Katharina
    Kuendgen, Andrea
    Roellig, Christoph
    Wermke, Martin
    Naumann, Ralph
    Bornhaeuser, Martin
    Giagounidis, Aristoteles
    Germing, Ulrich
    Hofmann, Wolf-Karsten
    Ehninger, Gerhard
    BLOOD, 2010, 116 (21) : 1630 - 1631
12345